Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Von Hoff DD, et al. Among authors: ma ww. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16. N Engl J Med. 2013. PMID: 24131140 Free PMC article. Clinical Trial.
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Jimeno A, et al. Among authors: ma ww. J Clin Oncol. 2008 Sep 1;26(25):4172-9. doi: 10.1200/JCO.2008.16.2347. J Clin Oncol. 2008. PMID: 18757332 Free PMC article. Clinical Trial.
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.
Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M. Garrido-Laguna I, et al. Among authors: ma ww. Br J Cancer. 2010 Aug 24;103(5):649-55. doi: 10.1038/sj.bjc.6605819. Epub 2010 Jul 27. Br J Cancer. 2010. PMID: 20664591 Free PMC article.
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Ma WW, et al. Clin Cancer Res. 2012 Apr 1;18(7):2048-55. doi: 10.1158/1078-0432.CCR-11-2813. Epub 2012 Feb 14. Clin Cancer Res. 2012. PMID: 22338014 Clinical Trial.
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Infante JR, Novello S, Ma WW, Dy GK, Bendell JC, Huff A, Wang Q, Suttle AB, Allen R, Xu CF, Ottesen LH, Burris HA 3rd, Adjei AA. Infante JR, et al. Among authors: ma ww. Invest New Drugs. 2013 Aug;31(4):927-36. doi: 10.1007/s10637-012-9900-0. Epub 2012 Nov 22. Invest New Drugs. 2013. PMID: 23179337 Clinical Trial.
240 results